top of page
02_A4-Studio-Mockups-Pack_Vol-01 copy.jpg

PharmD Reports

Therapeutic Guidance via

Our reports, provided as a supplementary review of your lab results, include detected findings, detailed pathogen explanations, and clinical interpretations of results to support your providers.

Treatment considerations for detected pathogens emphasize proper antimicrobial stewardship, promoting effective therapies and responsible prescribing practices.

Name: Sample patient DOB: 1/1/2000 (25 years) Gender: Female Facility: Sample Medical Facility Provider: Sample Healthcare Provider Allergies/Notes: PCN, Clindamycin Panel: UTI Sample ID: 1234 Collection Date: 7/21/2025 Reported Date:  7/22/2025                        Sample Type/Location: Urine DETECTED PATHOGENS Escherichia coli Detected - High > 10 6 copies/uL Gram-negative organism(s), may be responsible for UTI. Candida albicans Detected - Low < 10 4 copies/uL Fungus; may represent colonization. Symptomatic candiduria should be treated, however in the setting of co-detection of bacteria, it may be difficult to determine causative pathogens of symptomatic disease. Provider discretion should be utilized to determine if antifungal therapy is warranted in the setting of fungal and bacterial co-detection. DETECTED RESISTANCE GENES sul1 Detected - Medium Confers resistance to TMP/SMX. Expressed only by gram-negative organisms. PHARMD TREATMENT CONSIDERATIONS Regimens based on organisms most likely to be pathogenic. Microbial load considered when available. Medication Dose/Duration Renal Adjustment Considerations Nitrofurantoin (Macrobid) Uncomplicated UTI:  100 mg PO BID x 5 d Complicated UTI:  Avoid use Avoid use in pts with CrCl < 30 mL/min Coverage for: Escherichia coli • $15-19 for 5 day course † OR Fosfomycin (Monurol) Uncomplicated UTI:  3 g PO x 1 dose Complicated UTI: Avoid use None Coverage for: Escherichia coli • $28-56 for single dose † • May repeat dosing every 48-72 hrs up to a total of 1-3 doses OR Cefdinir (Omnicef) Uncomplicated UTI: 300 mg PO BID x 5 d Complicated UTI:  300 mg PO BID x 7 d CrCl < 30 mL/min: 300 mg PO daily Coverage for: Escherichia coli • $17-29 for 5 day course † • Safe to use in most PCN allergies (~5-10% general cross-reactivity), avoid with hx of anaphylaxis to PCN OR Ciprofloxacin (Cipro) Uncomplicated UTI: 500 mg PO BID x 3 d Complicated UTI: 500 mg PO BID x 5-7 d CrCl 30-50 mL/min: 250-500 mg PO every 12 hrs Crcl 5-29 mL/min: 250-500 mg PO every 18-24 hrs Coverage for: Escherichia coli • $13-24 for 3 day course † • FQ class-wide warnings include: CNS toxicity, peripheral neuropathy, myasthenia gravis, aortic dissection, tendinopathy, QT interval prolongation, C.difficile colitis † Based on available online coupons Additional Considerations Uncomplicated UTI defined as infection confined in the bladder in afebrile men or women. Complicated UTI defined pyelonephritis, febrile or bacteremic UTI, catheter-associated UTI, or prostatitis. If using an oral beta-lactam for pyelonephritis, consider administering a single dose of ceftriaxone IV/IM prior to course. For males in which acute prostatitis is suspected, fluoroquinolones and TMP/SMX are preferred due to reliable penetration of prostatic tissue.  Reviewed by: John PharmD (PS12345) Date: 7/22/2025 The following regimen(s) are based on generally accepted and peer-reviewed antimicrobial activity of specific agents against detected pathogens, resistance genes, and presumed diagnosis based on specimen source and resulting pathogens. Antimicrobial activity and efficacy of agents for treatment of detected pathogens is not guaranteed. Medication selection, dosages, durations, and considerations are in congruence with clinical practice guidelines (IDSA, CDC, AAP, etc), when guidance is available. Additional patient factors including but not limited to HPI, comorbidities, concomitant medications, etc. should be carefully evaluated in conjunction with listed treatment considerations. Clinical correlation and appropriate medical judgment is warranted prior to prescribing a course of Have a question about a report? Scan the QR code to chat with a pharmacist or call 904-618-3554. Powered by:

PharmD Reports

Sample

Wound Sample Report

Respiratory Sample Report

Choice PharmD sample report with QR code next to smartphone showing live pharmacist chat for provider support and treatment guidance.
Choice PharmD mobile chat example showing a live pharmacist answering provider questions about medication alternatives and treatment guidance.

A Live Pharmacist

Access To 

At Choice PharmD, we provide direct access to a trained, live pharmacist through our QR code to answer clinical questions (regimen clarification, allergies, drug-drug interactions, etc.) from your providers. Providers may reach us via a direct phone line or secure messaging system. We aim to be a valuable resource to your clients and provide optimal care for patients.

stewardship report layered.jpg

Stewardship Reports

Monthly

Our stewardship reports give a detailed breakdown of your lab’s pathogen and resistance gene detection. We compare your rates of detection to our entire network of PharmD labs, providing valuable insight for your laboratory. Additionally, we provide stewardship reports for facilities, featuring a breakdown of pathogen and resistance gene detection and tracking rates of notable pathogens (C. diff, multi-drug resistant pathogens, etc.) which may be needed for reporting to state health departments by a facility.

Stewardship report charts with pathogen and resistance gene data.
Stewardship report with pathogen and resistance gene charts and monthly pathogen table.
Choice PharmD monthly stewardship report sample with bar and pie charts showing pathogen detection rates, resistance trends, and positive sample counts.
Powered by: SENSITIVITY TABLE Sensitivity table is based on general antimicrobial sensitivity data obtained from tertiary references. The effect of resistance genes on antimicrobial activity is considered, however the correspondence of detected resistance genes to specific pathogens is not known. Antimicrobial activity of medications is not guaranteed. [++] Recommended: Agent is a first line therapy [+] Active: Agent is a potential alternative agent [±] Variable: Agent may be clinically effective in some settings, but may not be reliable in other settings [-] Not recommended: Pathogen likely resistant to agent [R] Not recommended: Resistance is likely present due to resistance gene(s) detected Klebsiella pneumoniae Staphylococcus aureus Staphylococcus epidermidis Penicillin G (IV/IM) - ± ± Penicillin VK (PO) - ± ± Nafcillin (IV) - ++ ++ Oxacillin (IV) - ++ ++ Dicloxacillin (PO) - ++ ++ Ampicillin (IV/PO) - ± ± Amoxicillin (PO) - ± ± Amoxicillin-Clav (PO) + + + Ampicillin-Sul (IV/IM) + + + Penicillins Piperacillin-Tazo (IV) ++ + + Cefazolin (IV/IM) + ++ ++ Cefoxitin (IV/IM) + + + Cefuroxime (IV/IM/PO) + + + Cefotaxime (IV/IM) + + + Ceftriaxone (IV/IM) ++ + + Ceftazidime (IV/IM) + - - Cefepime (IV/IM) + + + Ceftazidime-Avi (IV) + - - Ceftaroline (IV) + + + Ceftolozane-Tazo (IV) + - - Cefiderocol (IV) + - - Cefadroxil (PO) ± + + Cephalexin (PO) ± + + Cefixime (PO) + - - Cefpodoxime (PO) + + + Cephalosporins Cefdinir (PO) + + + Ertapenem (IV/IM) + + + Imipenem-Cil (IV) + + + Imp-cila-rele (IV) + + + Meropenem (IV) + + + Carbapenems Meropenem-Vabor (IV) + + + Klebsiella pneumoniae Staphylococcus aureus Staphylococcus epidermidis Monobactam Aztreonam (IV/IM) + - - Ciprofloxacin (IV/PO) + - - Delafloxacin (IV/PO) + + + Levofloxacin (IV/PO) + + + Fluoroquinolones Moxifloxacin (IV/PO) + + + Erythromycin (IV/PO) - ± ± Azithromycin(IV/PO) - ± ± Macrolides Clarithromycin (PO) - ± ± Doxycycline (IV/PO) R + + Minocycline (IV/PO) R + + Omadacycline (IV/PO) + + + Tetracyclines Tetracycline (PO) R + + Linacosamide Clindamycin (IV/PO) - + + Gentamicin (IV/IM) + ± ± Tobramycin (IV/IM) + - - Aminoglycosides Amikacin (IV/IM) + - - Oxazolid Linezolid (IV/PO) - + + Daptomycin (IV) - + + Vancomycin (IV) - + + Oritavancin (IV) - + + Glyco/Lipo Dalbavancin (IV) - + + Other TMP-SMX (IV/PO) ± + +

Sensitivity Tables

Comprehensive 

Available as an optional add-on to our PharmD reports, sensitivity tables provide a comprehensive list of medications along with their spectra of activity for detected organisms. Antimicrobial activity is based on general susceptibility data obtained from tertiary sources. Spectra of activity is adjusted for detected resistance genes if clinically relevant.

bottom of page